BREAST CAN­CER DRUGVITAL

Buckinghamshire Advertiser - - OPINION - JOHN ED­WARDS Hart­ley Court East Com­mon

IT is dev­as­tat­ing to hear that Kad­cyla – a cru­cial life-ex­tend­ing treat­ment for women with in­cur­able sec­ondary breast can­cer – faces be­ing with­drawn from the NHS, fol­low­ing the fail­ure of NICE and the drug’s man­u­fac­turer, Roche, to reach an agree­ment.

Kad­cyla can of­fer pa­tients pre­cious ex­tra months – even years – of good qual­ity time with their loved ones, with fewer side ef­fects than other treat­ments.

It is avail­able in many other coun­tries – in­clud­ing France, Ger­many and Aus­tralia – and un­less NICE’s draft de­ci­sion is over­turned next month, this fan­tas­tic med­i­cal ad­vance will by­pass pa­tients in Eng­land for­ever.

That’s why I’ve backed Breast Can­cer Now’s cam­paign to #Keep­Kad­cyla, which calls on NICE and Roche to ur­gently reach a deal to en­sure pa­tients in Eng­land are not de­nied this very ef­fec­tive treat­ment. There is very lit­tle time left for this de­ci­sion to be re­versed and I urge NICE and Roche to do ev­ery­thing in their power to keep this drug avail­able.

Newspapers in English

Newspapers from UK

© PressReader. All rights reserved.